Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6347374rdf:typepubmed:Citationlld:pubmed
pubmed-article:6347374lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:6347374lifeskim:mentionsumls-concept:C0684249lld:lifeskim
pubmed-article:6347374lifeskim:mentionsumls-concept:C0043227lld:lifeskim
pubmed-article:6347374lifeskim:mentionsumls-concept:C1516985lld:lifeskim
pubmed-article:6347374lifeskim:mentionsumls-concept:C0007131lld:lifeskim
pubmed-article:6347374lifeskim:mentionsumls-concept:C0008838lld:lifeskim
pubmed-article:6347374lifeskim:mentionsumls-concept:C0015133lld:lifeskim
pubmed-article:6347374lifeskim:mentionsumls-concept:C0042682lld:lifeskim
pubmed-article:6347374lifeskim:mentionsumls-concept:C1521750lld:lifeskim
pubmed-article:6347374lifeskim:mentionsumls-concept:C1563350lld:lifeskim
pubmed-article:6347374lifeskim:mentionsumls-concept:C1563351lld:lifeskim
pubmed-article:6347374lifeskim:mentionsumls-concept:C1518904lld:lifeskim
pubmed-article:6347374pubmed:issue7-8lld:pubmed
pubmed-article:6347374pubmed:dateCreated1983-9-20lld:pubmed
pubmed-article:6347374pubmed:abstractTextA combination of cisplatin (60 mg/m2 on Day 1), etoposide (120 mg/m2 on Days 3, 5, and 7), and vindesine (1.5 mg/m2 on Days 1 and 7), repeated every 3 weeks, was administered to 73 patients with non-small cell bronchogenic carcinoma. After two full courses, the results could be evaluated in 62 patients, 25 (40.3%) of whom responded (five complete responses, 20 partial responses). The median survival for the responding patients (12 months) was significantly superior (P = 0.02) to that of the nonresponding patients. There were three early toxic deaths from sepsis associated with granulocytopenia, and seven patients presented peripheral neuropathy. Although active in non-small cell bronchogenic carcinoma, the combination of cisplatin, etoposide, and vindesine does not appear to be superior to cisplatin-etoposide or cisplatin-vindesine when our previous experience and the results reported from other institutions are considered.lld:pubmed
pubmed-article:6347374pubmed:languageenglld:pubmed
pubmed-article:6347374pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6347374pubmed:citationSubsetIMlld:pubmed
pubmed-article:6347374pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6347374pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6347374pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6347374pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6347374pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6347374pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6347374pubmed:statusMEDLINElld:pubmed
pubmed-article:6347374pubmed:issn0361-5960lld:pubmed
pubmed-article:6347374pubmed:authorpubmed-author:KlasterskyJJlld:pubmed
pubmed-article:6347374pubmed:authorpubmed-author:MichelJJlld:pubmed
pubmed-article:6347374pubmed:authorpubmed-author:RocmansPPlld:pubmed
pubmed-article:6347374pubmed:authorpubmed-author:LibertPPlld:pubmed
pubmed-article:6347374pubmed:authorpubmed-author:MairesseMMlld:pubmed
pubmed-article:6347374pubmed:authorpubmed-author:NicaiseCClld:pubmed
pubmed-article:6347374pubmed:authorpubmed-author:WeertsDDlld:pubmed
pubmed-article:6347374pubmed:authorpubmed-author:SculierJ PJPlld:pubmed
pubmed-article:6347374pubmed:authorpubmed-author:FerremansWWlld:pubmed
pubmed-article:6347374pubmed:issnTypePrintlld:pubmed
pubmed-article:6347374pubmed:volume67lld:pubmed
pubmed-article:6347374pubmed:ownerNLMlld:pubmed
pubmed-article:6347374pubmed:authorsCompleteYlld:pubmed
pubmed-article:6347374pubmed:pagination727-30lld:pubmed
pubmed-article:6347374pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:6347374pubmed:meshHeadingpubmed-meshheading:6347374-...lld:pubmed
pubmed-article:6347374pubmed:meshHeadingpubmed-meshheading:6347374-...lld:pubmed
pubmed-article:6347374pubmed:meshHeadingpubmed-meshheading:6347374-...lld:pubmed
pubmed-article:6347374pubmed:meshHeadingpubmed-meshheading:6347374-...lld:pubmed
pubmed-article:6347374pubmed:meshHeadingpubmed-meshheading:6347374-...lld:pubmed
pubmed-article:6347374pubmed:meshHeadingpubmed-meshheading:6347374-...lld:pubmed
pubmed-article:6347374pubmed:meshHeadingpubmed-meshheading:6347374-...lld:pubmed
pubmed-article:6347374pubmed:meshHeadingpubmed-meshheading:6347374-...lld:pubmed
pubmed-article:6347374pubmed:meshHeadingpubmed-meshheading:6347374-...lld:pubmed
pubmed-article:6347374pubmed:meshHeadingpubmed-meshheading:6347374-...lld:pubmed
pubmed-article:6347374pubmed:meshHeadingpubmed-meshheading:6347374-...lld:pubmed
pubmed-article:6347374pubmed:meshHeadingpubmed-meshheading:6347374-...lld:pubmed
pubmed-article:6347374pubmed:meshHeadingpubmed-meshheading:6347374-...lld:pubmed
pubmed-article:6347374pubmed:articleTitleCombination chemotherapy with cisplatin, etoposide, and vindesine in non-small cell lung carcinoma: a clinical trial of the EORTC lung cancer working party.lld:pubmed
pubmed-article:6347374pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6347374pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:6347374pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6347374lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6347374lld:pubmed